National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Gemtuzumab ozogamicin (Mylotarg®) which is indicated for combination therapy with daunorubicin and cytarabine for the treatment of patients age 15 years and above with previously untreated, de novo CD33 positive AML, except acute promyelocytic leukaemia.

NCPE Assessment Process Completed
Rapid review commissioned 21/06/2018
Rapid review completed 17/07/2018
Rapid Review outcome A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of gemtuzumab ozogamicin compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by the HSE 31/07/2018
Pre-submission consultation with Applicant 03/09/2018
Submission received from Applicant 15/11/2018
Preliminary review send to Applicant 06/03/2019
NCPE assessment re-commenced 01/04/2019
Factual accuracy sent to Applicant 04/06/2019
NCPE assessment re-commenced 17/06/2019
NCPE assessment completed 04/07/2019
NCPE assessment outcome Following NCPE assessment of the company submission, gemtuzumab ozogamicin (Mylotarg®) (with daunorubicin and cytarabine) is not considered cost effective for the treatment of patients ≥ 15 years with previously untreated, de novo CD33-positive acute myeloid leukaemia, except acute promyelocytic leukaemia, and therefore is not recommended for reimbursement at the submitted price.

Summary